medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2009, Number 3

<< Back Next >>

Rev Invest Clin 2009; 61 (3)

Prevalence of hypokalemia in patients with methylprednisolone pulse therapy

Tamez-Pérez HE, Cisneros-Pérez V, Cedillo-Rodríguez JA, Díaz-DeLeón-González E, Torres-Valenzuela M, Tamez-Peña AL, Forsbach-Sánchez G, Gutiérrez-Hermosillo H

Language: Spanish
References: 19
Page: 194-197
PDF size: 78.48 Kb.


ABSTRACT

Objective. To determine the prevalence of hypokalemia in patients with methylprednisolone pulse therapy. Design. We carried out a descriptive, cross-sectional study. Material and methods.We enrolled 110 outpatients who received pulse doses of 1 g of intravenous methylprednisolone for three consecutive days. Demographic variables, serum electrolytes and an electrocardiogram were documented. Results. The study group consisted of 31 men (28.2%) and 79 women (71.8%). Average age was 40 ± 13.6 years. Mild hypokalemia was present in 19 patients (17.27% [95% CI 9.75-24.79]); moderate potassium levels were found in just one patient 0.9% [IC95 0.023-4.96]); no cases of severe hypokalemia occurred. Total prevalence was 18.18% (95% CI 10.5-25.8). There were no significant electrocardiographic changes. Discussion and conclusion. Mild and moderate hypokalemia was 18.18% without clinical or electrocardiographic consequences. Since there were no cases of severe hypokalemia, close monitoring of potassium levels should be restricted to those patients with other risk factors.


REFERENCES

  1. Williams GH, Dluhy RG. Enfermedades de la corteza suprarrenal. En: Fauci, Braunwald, Kasper, Hauser, Longo, Janeson, Loscalzo (eds.). Harrison Principios de Medicina Interna 17a Ed. México: Mc Graw Hill Interamericana; 2008, p. 2247-69.

  2. Marcocci C, Baretelena L, Tanda M, Manetti L, Dell’unto E, Rocchi R, Barbesino G, et al. Comparison of the Effectiveness and Tolerability of Intravenouns or Oral Glucocorticoids As sociated with Orbital Radiotherapy in the Management of Severe Graves’ Ophtalmopathy: Results of a Prospective, Single- Blind, Randomized Study. J Clin Endocrinol Metab 2001; 86: 3562-7.

  3. Garret R, Paulus H. Complications on intravenous methylprednisolone pulse therapy. Arthritis Rheum 1980; 23: 677.

  4. Miyashita Y, Monden T, Yamamoto K, Matsumura M, Kawagaoe N, Iwata C, et al. Ventricular Fibrillation Due to Severe Hypokalemia Induced by Steroid Treatment in a Patient with Thyrotoxic Periodic Paralysis. Intern Med 2006; 45: 11-3.

  5. Rojeau JC. Pulse glucocorticoid in Therapy. The “big shot” revisited. Arch Dermatol 1996; 132(12): 1499-502.

  6. Gennari F. Hypokalemia. N Engl J Med 1998; 339: 451-8.

  7. Schaefer TJ, Wolford RW. Disorders of potassium. Emerg Med Clin North Am 2005; 23(3) 723-47.

  8. Paltiel O, Salakov E, Ronen I, Berg D, Israeli A. Management of Severe hypokalemia in Hospitalized Patients. Arch Intern Med 2001; 161(8): 1089-95.

  9. Juchet H, Arlet P, Ollier S, Montane de la Roque P, Le Tallec Y. Bolus of methylprednisolone and Horton’s disease/rhizomelic pseudo-polyarthritis. Preliminary results of a pilot study of treating the bolus with low doses of corticoids. Ann Med Interne (Paris) 1992; 143(2): 85-8.

  10. Peters ND, Ejstrup L. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scand J Rheumatol 1992; 21(3): 134-8.

  11. Mignogna MD, Lo Muzio L, Ruoppo E, Fedele S, Lo Russo L, Bucci E. High-dose Intravenous pulse methylprednisolone in the treatment of severe oropharingeal pemphigus: a pilot study. J Oral Pathol Med 2002; 31(6): 339-44.

  12. Hoch S, Schur PH. Methylprednisolone pulse therapy for lupus nephritis: a follow up study. Clin Exp Rheumatol 1984; 2(4): 313-20.

  13. Feldman-Billiard S, Lissak B, Benrabah R, Heron E. Intravenous pulse methylprednisolone therapy in eye disease: effect on glucose tolerance. Ophtalmology 2003; 110(12): 2369-71.

  14. Roden DM. Drug-Induced Prolongation of the QT Interval. N Engl J Med 2004; 350: 1013.

  15. Chibane S, Feldman-Billard S, Rossignol I, Kassaei R, Mihoubi- Mantout F, Heron E. Short-term tolerance of three days pulse methylprednisolone therapy: a prospective study in 146 patients. Rev Med Interne 2005; 26(1): 20-6.

  16. Paltiel O, Salakhov E, Ronen I, Berg D, Israeli A. Management of Severe Hypokalemia in Hospitalized Patients A Study of Quality of Care Based on Computerized Databases. Arch Intern Med 2001; 161: 1089-95.

  17. Wongraoprasert S, Buranasupkajorn P, Sridama V, Snabbon T. Thyrotoxic periodic paralysis induced by pulse methylprednisolone. Intern Med 2007; 46: 1431-3.

  18. Menon V, Mehrotra A, Saxena R, Jaffery NF. Comparative evaluation of dexametasone for treatment of primary typical optic neuritis. Indian JC 2007; 55: 355-9.

  19. Tamez Pérez HE, Gutiérrez Hermosillo H, Cedillo Rodriguez J, Mora Torres N, Hernández Coria M, Gómez de Ossio M. Tratamiento con insulina en el paciente hospitalizado con diabetes mellitus tipo 2 ¿única opción? Med Int Mex 2007; 23: 196-9.




2020     |     www.medigraphic.com